Drug Shows Potential to Combat Exaggerated Inflammation Linked to COVID-19

The discovery of an inflammasome-inhibiting drug opens up novel therapies for conditions such as autoimmune and neurodegenerative disorders.

In COVID-19 patients, niclosamide, the anti-helmintic drug inhibits SARS-CoV-2 replication as well as the exacerbated inflammatory response that leads to death.

More research is needed to find out whether the effects, described in an article published in Science Advances, are confirmed in patients with the disease, and according to the authors this will require the development of a novel formulation of the drug, as the one currently available from pharmacies is orally administered and would not affect the lungs.

The Antiviral Action of Niclosamide

“The commercially available niclosamide pills aren’t absorbed by the stomach and therefore act against intestinal worms. They won’t be of any use to combat COVID-19 if taken orally. To surmount this problem, it will be necessary to develop a formulation that delivers the drug directly to the lungs,” said Dario Zamboni, last author of the article.

Mental Health during COVID-19: Top Tips to Manage COVID Anxiety, Depression
Coping with mental health during COVID-19 is the need of the hour. The article highlights top tips to manage mental health and well-being during the pandemic.

‘The anti-inflammatory effects of niclosamide observed in the study were due to inhibition of an immune system mechanism known as the inflammasome, a protein complex present in the interior of defense cells.’

Zamboni is a professor at the Ribeirão Preto Medical School (FMRP-USP) and affiliated with the Center for Research on Inflammatory Diseases (CRID), a Research, Innovation and Dissemination Center (RIDC) funded by FAPESP. The study was also funded by FAPESP via two other projects (19/11342-6 and 20/04964-8).

According to Zamboni, the anti-inflammatory effects of niclosamide observed in the study were due to the inhibition of an immune system mechanism known as the inflammasome, a protein complex present in the interior of the defense cells. When this cellular machinery is activated, pro-inflammatory molecules called cytokines are produced to warn the immune system that more defense cells need to be sent to the site of the infection.

Previous research by the FMRP-USP group showed that inflammasomes in severe COVID-19 patients are typically more activated than normal and remain so even after the virus has been eliminated from the patient, causing an exaggerated systemic inflammatory response known as a cytokine storm that injures the lungs and other organs (more at: agencia.fapesp.br/39411/).

Test your Knowledge on Coronavirus (COVID-19)
Coronavirus is a large positive-strand RNA virus that is surrounded by a protein envelope. The virus obtains its name from the S protein spikes on its surface, which resemble a crown. The overall pattern of increasing coronavirus cases is shown to spike up with the “second wave” of COVID-19.

With spiking effects of the second wave of coronavirus, the best way to keep it at bay is to follow COVID-appropriate safety practices like wearing a mask, regularly cleaning your hands, and coughing into a bent elbow or tissue along with physical distancing (6 feet about 2 arm's length), that may help evade the severity of COVID-19 infection.

Zamboni stressed, however, that niclosamide should not be used prophylactically to prevent exacerbated inflammation. “A little inflammation is important to combat infection by pathogenic microorganisms,” he said. “Exaggerated inflammation is the problem, as is often the case in severe COVID-19. We’re not recommending prophylactic use of the drug, since this could even hinder a recovery by mild or moderate COVID-19 patients.” Niclosamide has been on the market for many years and is mainly prescribed to treat taeniasis (tapeworm infection). It has recently aroused interest among researchers due to claims of potential antiviral action.

Compost Products Found to Contain Legionella Bacteria
Legionella bacteria exist in a significant number of commercial compost products, a study conducted at the University of Strathclyde has found.

According to the authors of the Science Advances article, niclosamide promotes autophagy, a vital process that removes and recycles unwanted or damaged molecules from the body’s cells. When this process of autophagic cell cleansing is induced, old organelles are destroyed, cellular components are recycled and inflammasomes are deactivated. The process also inhibits replication of SARS-CoV-2 inside cells.

The researchers began the study by screening 2,560 compounds, many of which are already used in humans, in a search for substances capable of inflammasome modulation. This involved infecting human defense cells in vitro with Legionella, a bacterium known for inflammasome activation.

Legionella Testing Needs to be Improved
A recent study from Rhode Island Hospital has pointed out that testing patients for possible community-acquired pneumonia due to Legionella needs improvement to enable a more accurate diagnosis.

After selecting the three most promising drugs, the researchers tested them on mice infected with SARS-CoV-2 and white blood cells from COVID-19 patients. They also tested the effects of these drugs on macrophages and monocytes, front-line immune cells intensely involved in COVID-related inflammasomes. Niclosamide produced the best results.

To investigate its antiviral action, the researchers tested it on monocytes infected in vitro with SARS-CoV-2. “Niclosamide’s antiviral action was already known. Indeed, phase 1 clinical trials involving treatment of COVID-19 patients with the drug are under way right now. Our discovery that it induces autophagy and inhibits inflammasomes offers additional information on the immunomodulatory functions of this highly promising drug,” Zamboni said.

“The study focused on COVID-19, but in theory niclosamide should also promote inflammasome inhibition in these other cases. Our results point to numerous other research possibilities,” Zamboni said.

Source-Eurekalert